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Background: Bloodstream infections (BSI) due to carbapenem-resistant (C-R) Klebsiella pneumoniae (Kp) are of global
concern from both clinical and public health standpoints. This retrospective study aimed to describe C-R Kp BSI
epidemiology in a large teaching hospital in northern Italy.
Methods: Between 1 January 2007 and 31 December 2014, annual incidences both of C-R Kp BSI and of
carbapenem-susceptible (C-S) Kp BSI were calculated as the number of events per 10,000 patient-days. A Chi square test
for linear trend was used to assess the change in the incidence of C-R Kp BSI and C-S Kp BSI over the study period. Crude
30-day mortality rates were provided both for C-R Kp BSI and for C-S Kp BSI.
Results: From 2007 to 2014, we observed 511 episodes of Kp BSI, 349 of which were caused by C-R Kp (68.3 %). The
incidence of C-R Kp BSI considerably increased from 0.04/10,000 patient-days in 2007 to 1.77/10,000 patient-days in 2014
(Chi square for trend p < 0.001). The highest incidence of C-R Kp BSI was observed in intensive care units (ICUs), with a
peak of 22.01 C-R Kp BSI/10,000 patient-days in 2012. A less marked but significant increase of C-S Kp BSI was also
observed (Chi square for trend p = 0.004). Crude 30-day mortality was 36.1 % in patients with C-R Kp BSI and 23.5 % in
those with C-S Kp BSI.
Conclusions: During the study period, we observed a dramatic increase in the incidence of C-R Kp BSI in our hospital.
More concerted infection-control efforts are needed to contain this alarming C-R Kp diffusion.
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Bloodstream infections (BSI) due to carbapenem-resistant
(C-R) Klebsiella pneumoniae (Kp) are of global concern
from both clinical and public health standpoints. Indeed,
these severe infections are caused by rapidly spreading
clones that are frequently resistant to almost all the antibi-
otics used in the everyday clinical practice [1–6].* Correspondence: daniele.roberto.giacobbe@gmail.com
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(http://creativecommons.org/publicdomain/zeOccurring especially across Southern Europe, the rapid
diffusion of C-R Kp has worryingly impressed the
medical community, and several guidelines have been re-
cently developed to reduce the spread of these difficult-
to-treat gram-negative rods [7–9]. In Italy, carbapenem
resistance among blood Kp isolates has dramatically
increased from 1.3 % in 2009 to 29.1 % in 2012, and even
higher rates of 34.3 % have been reported in 2013 [10, 11].
With the aim of more clearly investigate this alarming C-R
Kp diffusion, we retrospectively assessed the epidemiology
of C-R Kp BSI in a large teaching hospital in northern Italy
over a 8-year period.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Data collection and definitions
We performed a retrospective study in IRCCS AOU San
Martino – IST, a 1,300-beds tertiary adult acute-care
teaching hospital in Genoa, Italy. Between 1 January
2007 and 31 December 2014, numbers of hospital patient-
days were obtained from the digital archives of patients’
clinical charts. Then, numbers of both carbapenem-
susceptible (C-S) BSI and C-R Kp BSI were identified
through the computerized microbiology laboratory data-
base. The completeness and quality of laboratory data was
successfully assessed by matching the hospital admission
code with data obtained by clinical charts.
Only health-care associated C-R Kp BSI were consid-
ered for the analysis. According to the European Center
for Disease Control and prevention (ECDC) definitions, a
health-care associated C-R Kp BSI was defined as a positive
blood culture collected at least 48 h after hospital admis-
sion, or within 48 h from hospital admission in those pa-
tients who had been discharged in the preceding two days
[12]. For patients with multiple episodes of C-R Kp BSI, a
novel event was considered as independent if occurring at
least 30 days after the last positive blood culture [12].
This epidemiological analysis was performed within
the Institutional surveillance of C-R Kp BSI that is peri-
odically reported to the Regional Health Authority as a
component of the Regional Plan for the Healthcare-
associated infections Prevention and Control, approved
by regional and national laws [13, 14]. The study in-
volved the analysis of existing anonymized clinical and
laboratory data. An informed consent for the use of
anonymized data for scientific purposes is signed by all
patients admitted to IRCCS AOU San Martino – IST
and included in surveillance databases. The study has
been approved by the Regional Ethics Committee of
Liguria Region.
Microbiology
The Vitek 2 system (bioMérieux, Marcy l’Etoile, France)
was used for Kp identification and antimicrobial suscep-
tibility testing. The interpretative breakpoints were based
on the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) criteria (EUCAST breakpoint
tables for interpretation of MICs and zone diameters,
version 4.0, 2014; http://www.eucast.org). For the ana-
lysis of data, Kp isolates which were resistant to one or
more carbapenems tested in our institution (i.e., ertape-
nem, imipenem, or meropenem) were considered to be
C-R, while isolates showing full or intermediate suscepti-
bility to all tested carbapenems were classified as C-S.
Statistical analysis
The primary study analysis aimed to establish the annual
incidences of C-R Kp BSI during the study period.Annual incidences of C-R Kp BSI with their 95 % confi-
dence intervals (CI) were calculated as the number of
events per 10,000 patient-days. In addition, annual inci-
dences of C-R Kp BSI were also stratified by subgroups
according to the ward where the diagnosis of C-R Kp
BSI was made (i.e., intensive care units [ICUs], medical
wards, surgical wards, or rehabilitation wards). A Chi
square test for linear trend was used to assess the
change in the incidence of C-R Kp BSI in our hospital
over the study period.
An additional aim was to detail the overall trends in
the incidence of Kp BSI. Therefore, annual incidences of
health-care associated C-S Kp BSI were also calculated,
by means of the methods described above. Finally, crude
30-day mortality rates were assessed both for C-R Kp
BSI and for C-S Kp BSI.
All the analyses were performed using Epi-Info 7.0
(Centers for Disease Control and Prevention, CDC,
Atlanta, GA, USA) and the SPSS Statistics version 20.0
(IBM Corp., Armonk, NY, USA).Results
Between January 2007 and December 2014, we identified
511 episodes of Kp BSI, 349 of which were caused by C-
R Kp (68.3 %). These episodes occurred in 327 patients,
of whom 19 had recurrent infections (5.8 %). The me-
dian age of patients was 68 years (interquartile range
[IQR] 57–76). As many as 231/349 C-R Kp BSI occurred
in males (66.2 %), thus defining a 2:1 male to female
ratio. The median time to C-R Kp BSI diagnosis from
hospital admission was 24 days (IQR 12–45), and the
median length of hospital stay was 52 days (IQR 30–90).
During the study period, the overall incidence of C-R
Kp BSI was 0.92/10,000 patient-days, increasing from
0.04/10,000 patient-days in 2007 to 1.77/10,000 patient-
days in 2014 (Chi square for trend p < 0.001). Detailed
year-by-year incidences of C-R Kp BSI are outlined in
Table 1, which also reports annual incidences of C-R Kp
BSI according to wards’ subgroups. As shown in the
table, C-R Kp BSI were first observed in 2007, reflecting
a limited cluster in ICUs. No C-R Kp BSI occurred in
2008, while they reappeared since 2009, with annual
incidences increasing from 0.56/10,000 patient-days in
2009 to 1.75/10,000 patient-days in 2012. After a tem-
porary decrease in 2013, the incidence of C-R Kp BSI
rose again to 1.77/10,000 patient-days in 2014.
Overall, the incidence of Kp BSI (C-R plus C-S)
increased from 0.50/10,000 patient-days in 2007 to 2.42/
10,000 patient-days in 2014 (Chi square for trend p <
0.001). The singular trends of C-R Kp BSI and C-S Kp
BSI over the study period are depicted in Fig. 1. As
shown in the figure, the overall increase in the incidence
of Kp BSI was mostly due to C-R Kp BSI, although a less
Table 1 Annual incidences of health-care associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections
Incidence per 10,000 patient-days (95 % CI)
Year No. of episodes Ward where the diagnosis of C-R Kp BSI was made
Overall ICU Surgical wards Medical wards Rehabilitation wards
2007 2 0.04 (0.01 – 0.17) 1.15 (0.29 – 4.59) - - -
2008 0 - - - - -
2009 27 0.56 (0.38 -0.82) 12.70 (8.44 – 19.1) 0.14 (0.04 – 0.57) 0.04 (0 – 0.28) 0.60 (0.09-4.27)
2010 39 0.83 (0.60-1.13) 17.18 (11.94 – 24.71) 0.08 (0.01 – 0.55) 0.32 (0.16 – 0.64) 0.44 (0.06 – 3.12)
2011 59 1.22 (0.94-1.57) 21.06 (15.40-28.81) 0.69 (0.36-1.32) 0.36 (0.19 – 0.69) 0.60 (0.02 – 2.39)
2012 83 1.75 (1.41-2.17) 22.01 (16.09 – 30.11) 1.55 (0.99-2.43) 0.96 (0.64 -1.44) 0.44 (0.11 – 1.76)
2013 60 1.30 (1.01 – 1.68) 18.17 (12.98 – 25.42) 0.61 (0.29 – 1.29) 0.72 (0.44 – 1.17) 0.48 (0.15 – 1.48)
2014 79 1.77 (1.42 – 2.20) 18.79 (13.62 – 25.93) 0.66 (0.31 – 1.37) 1.32 (0.92 – 1.89) 0.98 (0.41 – 2.36)
C-R Kp BSI carbapenem-resistant Klebsiella pneumoniae bloodstream infections, ICU intensive care unit
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observed (Chi square for trend p = 0.004).
Finally, crude 30-day mortality was higher in patients
with C-R Kp BSI than in those with C-S Kp BSI (36.1 vs.
23.5 %, respectively). However, this comparison was not
further considered in our analyses, since it could not be
adjusted for some important clinical confounders (e.g.,
severity of illness, type of antibiotic therapy) that were
not explored in this epidemiologic study.
Discussion
From 2007 to 2014 we noticed an impressive increase of
more than 300 % in the incidence of Kp BSI in our hos-
pital, that was mostly driven by C-R strains. This finding
is of particular concern, since C-R Kp BSI carry a heavy
burden in terms of morbidity and mortality [3–6].Fig. 1 Annual incidences of health-care associated Klebsiella pneumoniae bA worrisome and persistent increase of carbapenem-
resistance among Kp isolates has been reported in Italy
since 2005, with current national rates being as high as
34 % [11, 12]. Our experience confirms this picture,
since we observed a rapid increase in the incidence of
C-R Kp BSI starting from 2007, that peaked at 1.75/
10,000 patient-days in 2012. A temporary decrease was
then observed in 2013, possibly because of the intensifi-
cation of our hospital-based infection control measures
(i.e., rapid identification of colonized and/or infected pa-
tients trough a centralized and computerized laboratory-
based alert system, patient dedicated use of gowns and
gloves) that occurred at that time. Starting from the
same period, an active surveillance of colonized patients
and their contacts was also implemented, by means of
rectal swab and according to European guidelines [9].loodstream infections (C-R and C-S)
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the incidence of infections due to multidrug resistant
gram negatives, including C-R Kp [15–19]. However, after
the temporary decrease mentioned above, the incidence of
C-R Kp BSI in our hospital rose again to 1.77/10,000
patient-days in 2014. Although a lack of adherence to con-
tention measures might have occurred in some cases,
another factor possibly underlie this increase that mostly
occurred outside the ICU. Indeed, we recently observed
that some C-R Kp intestinal carriers in low risk wards (i.e.,
wards other than ICU or cancer wards) might not be
considered at risk (and thus not screened) even if all
recommended infection-control protocols are adopted
[20]. This finding suggests that a considerable number of
unknown carriers might be circulating in our hospital that
are not subjected to contact precautions because of the
unawareness of their status. This possibility is rather
worrisome, since it could lead to an uncontrolled C-R
Kp diffusion, thus fueling the reservoir of patients who
possibly develop C-R Kp BSI [20, 21]. In such an
uncontrolled endemic setting, further infection-control
efforts (e.g., a dynamic redefinition of wards to adopt
universal screening through regular point-prevalence
surveys) might be necessary to successfully counteract
the alarming spread of C-R Kp.
The present study has some important limitations.
First, we could not depict the true pattern of C-R Kp dif-
fusion, since only blood C-R Kp isolates were considered.
However, C-R Kp BSI can provide a reliable picture of this
diffusion, since blood cultures are collected from nearly all
patients with C-R Kp BSI because of the symptomatic
nature of the infection. Conversely, any possible estima-
tion based on colonized patients would have been affected
by an important selection bias due to the differences in
the number of screened patients across the study years.
Second, the retrospective nature of the study prevented us
from investigating the degree of compliance to infection-
control measures during the study period, as well as the
molecular characteristics of C-R Kp isolates. In this
regard, a major limitation is the lack of information about
both the clonal type of Kp isolates and their mechanisms
of resistance to carbapenems. Finally, this was a single
center study, and incidences of C-R Kp BSI may differ sig-
nificantly across centers. Therefore, any extrapolation of
our findings to other settings should be made with due
caution.
Conclusions
In our hospital a dramatic increase in the incidence of
C-R Kp BSI occurred from 2007 to 2014 that appeared
to be only temporarily arrested by the intensification of
hospital-based infection-control measures. More concerted
efforts are necessary to tackle this alarming C-R Kp diffu-
sion. Because of the dramatic shortage in antibiotics activeagainst C-R Kp, further improvements in our infection-
control protocols are also of paramount importance to
curtail the high number of deaths due to C-R Kp BSI.
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